Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.

Guardado en:

Detalles Bibliográficos
Autores principales:	Georgia Zoumpoulidou, Carlos Alvarez-Mendoza, Caterina Mancusi, Ritika-Mahmuda Ahmed, Milly Denman, Christopher D. Steele, Maxime Tarabichi, Errin Roy, Lauren R. Davies, Jiten Manji, Camilla Cristalli, Katia Scotlandi, Nischalan Pillay, Sandra J. Strauss, Sibylle Mittnacht
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29d2b65339524853a5548dbf68b35ca4
record_format	dspace
spelling	oai:doaj.org-article:29d2b65339524853a5548dbf68b35ca42021-12-05T12:21:49ZTherapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma10.1038/s41467-021-27291-82041-1723https://doaj.org/article/29d2b65339524853a5548dbf68b35ca42021-12-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-27291-8https://doaj.org/toc/2041-1723RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.Georgia ZoumpoulidouCarlos Alvarez-MendozaCaterina MancusiRitika-Mahmuda AhmedMilly DenmanChristopher D. SteeleMaxime TarabichiErrin RoyLauren R. DaviesJiten ManjiCamilla CristalliKatia ScotlandiNischalan PillaySandra J. StraussSibylle MittnachtNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Georgia Zoumpoulidou Carlos Alvarez-Mendoza Caterina Mancusi Ritika-Mahmuda Ahmed Milly Denman Christopher D. Steele Maxime Tarabichi Errin Roy Lauren R. Davies Jiten Manji Camilla Cristalli Katia Scotlandi Nischalan Pillay Sandra J. Strauss Sibylle Mittnacht Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
description	RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.
format	article
author	Georgia Zoumpoulidou Carlos Alvarez-Mendoza Caterina Mancusi Ritika-Mahmuda Ahmed Milly Denman Christopher D. Steele Maxime Tarabichi Errin Roy Lauren R. Davies Jiten Manji Camilla Cristalli Katia Scotlandi Nischalan Pillay Sandra J. Strauss Sibylle Mittnacht
author_facet	Georgia Zoumpoulidou Carlos Alvarez-Mendoza Caterina Mancusi Ritika-Mahmuda Ahmed Milly Denman Christopher D. Steele Maxime Tarabichi Errin Roy Lauren R. Davies Jiten Manji Camilla Cristalli Katia Scotlandi Nischalan Pillay Sandra J. Strauss Sibylle Mittnacht
author_sort	Georgia Zoumpoulidou
title	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
title_short	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
title_full	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
title_fullStr	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
title_full_unstemmed	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
title_sort	therapeutic vulnerability to parp1,2 inhibition in rb1-mutant osteosarcoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4
work_keys_str_mv	AT georgiazoumpoulidou therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT carlosalvarezmendoza therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT caterinamancusi therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT ritikamahmudaahmed therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT millydenman therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT christopherdsteele therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT maximetarabichi therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT errinroy therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT laurenrdavies therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT jitenmanji therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT camillacristalli therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT katiascotlandi therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT nischalanpillay therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT sandrajstrauss therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma AT sibyllemittnacht therapeuticvulnerabilitytoparp12inhibitioninrb1mutantosteosarcoma
_version_	1718372005654298624

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Ejemplares similares